Versuchen GOLD - Frei

Is APAC Edging Closer to Clinical Application of Single-cell Tech?

BioSpectrum Asia

|

BioSpectrum Asia Oct 2023

Asia Pacific APAC) is expected to be a major contributor to the growth of single cell technology as the market is driven by factors such as the growing demand for personalised medicine, advancements in sequencing technologies, and the increasing use of single cell analysis in drug discovery. While Japan is currently the fastest-growing country in the APAC single-cell analysis market, Singapore, China, and India are showing significant progress in adopting this technology.

- Anusha Ashwin

Is APAC Edging Closer to Clinical Application of Single-cell Tech?

A single cell contains multiple omics including genome, epigenome, transcriptome, and others. The completion of the Human Genome Project in 2003 was the beginning of deciphering the biological meaning of the three billion nucleotides in the human genome. Later, a key technological milestone was the release of several massively parallel DNA sequencing (next-generation sequencing) platforms in 2005 and 2007, which allowed for generating sequencing reads of billions of base pairs in a few days at a cost of less than $1,000. Moving on, the single-cell omics sequencing research started in 2009 when the single-cell RNA sequencing (scRNA-seq) assay was described.

In recent years, more and more single-cell technologies have been developed. A vast amount of single-cell omics data has been generated by large projects globally, such as the Human Cell Atlas, the Mouse Cell Atlas, the Mouse RNA Atlas, the Mouse ATAC Atlas, and the Plant Cell Atlas. Based on these single-cell big data, thousands of bioinformatics algorithms for quality control, clustering, cell-type annotation, developmental inference, cell-cell transition, cell-cell interaction, and spatial analysis are developed. Some of the most common single-cell technology methods include Single-cell RNA sequencing (scRNA-seq); Single-cell proteomics; Single-cell epigenomics; Single-cell imaging; and Single-cell electrophysiology.

Notably, the first successful demonstration of single cell RNA sequencing was published in 2009 by a team of researchers at the University of Washington led by Dr Jay Shendure and Dr Cole Trapnell. They used a method called Smart-seq to amplify and sequence the mRNA from individual mouse blastomeres (early-stage embryonic cells) and demonstrated that the technique could be used to profile gene expression in individual cells.

WEITERE GESCHICHTEN VON BioSpectrum Asia

BioSpectrum Asia

Leadgene Biosolutions expands product portfolio for metabolic research

Leadgene Biosolutions has announced the expansion of its product portfolio following its strategic integration into Leadgene Biomedical.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Korea, Philippines to develop nextgeneration tuberculosis diagnosis

The Korea National Institute of Health (NIH), under the Korea Disease Control and Prevention Agency (KDCA) is entering into a research agreement with the Research Institute for Tropical Medicine (RITM) of the Philippines to initiate an international collaborative research project aimed at developing next-generation tuberculosis (TB) diagnostic technologies.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Australia and Indonesia achieve WHO Listed Authority status in medical products regulation

The World Health Organization (WHO) has formally recognised the regulatory authorities for medical products of Australia and Indonesia as WHO Listed Authorities (WLAs), an achievement that underscores growing global confidence in regulatory systems across diverse regions and income settings.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries

Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Aevice Health announces expansion into Australian market

AeviceMD Monitoring System, a non-invasive wearable respiratory monitoring solution developed by Singapore-based Aevice Health, has been included in the Australian Register of Therapeutic Goods (ARTG) as a Class IIa medical device.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Insilico Medicine lists on Hong Kong Stock Exchange, exhibiting largest Hong Kong biotech IPO

Insilico Medicine, a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Australia provides cheaper medicines for inflammatory & rare liver disease and MS

Australians living with a range of debilitating conditions including juvenile arthritis, rare liver disease and multiple sclerosis (MS) will pay less for newly Pharmaceutical Benefits Scheme (PBS) listed medicines, as directed by the Australian Government.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Valneva and Serum Institute of India discontinue Chikungunya vaccine license agreement

France-based Valneva SE, a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company, have mutually agreed to discontinue their license agreement for Valneva's single-shot chikungunya vaccine.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Santhera licenses AGAMREE to Nxera Pharma in $205 M Asia-Pacific deal

Swiss firm Santhera Pharmaceuticals has signed an exclusive licensing agreement with Nxera Pharma UK for the development, manufacturing and commercialisation of AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in Japan, South Korea, Australia and New Zealand.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

AdCella and Shanghai Cell Therapy Group launch global collaboration for cancer therapy

Australia-based AdAlta, developer of next generation cell and protein therapeutic products, and its cellular immunotherapy subsidiary, AdCella have signed a major development agreement with Shanghai Cell Therapy Group (SHcell) to bring an innovative cancer treatment, BZDS1901, to markets outside China.

time to read

1 min

BioSpectrum Asia Feb 2026

Translate

Share

-
+

Change font size